Authorization

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)

BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming August 9, 2021deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the "Class Period").Investors suffering losses on their AcelRx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.AcelRx is a pharmaceutical company that develops therapies for the treatment of acute pain. One of its lead product candidates is DSUVIA, which has been approved by the U.S. Food and Drug Administration ("FDA") for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings. On February 16, 2021, AcelRx disclosed that it had received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, the FDA concluded that certain of AcelRx's promotional communications "make false or misleading claims and representations about the risks and efficacy of DSUVIA," and "[t]hus . . . misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative." On this news, AcelRx's stock price fell $0.21 per share, or 8.37%, to close at $2.30 per share on February 16, 2021, thereby injuring investors.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2022    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930